Are Compounded Semaglutide Going Away? The Real Timeline, Not the Headlines

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide remains legal as of April 2026 because FDA's official drug shortage list still includes semaglutide injection (last verified April 22, 2026)
• FDA can remove semaglutide from the shortage list with 60 days notice, which would trigger a gradual phase-out of compounding access over 60-90 days
• Novo Nordisk announced in March 2024 they resolved manufacturing constraints, but FDA has not yet declared the shortage resolved because demand still exceeds consistent supply
• The most likely timeline for compounding restrictions is Q4 2026 through Q1 2027, based on current production capacity data and FDA's historical shortage resolution patterns

Direct answer (40-60 words)

Compounded semaglutide is not going away immediately. It remains legal while FDA's drug shortage designation continues. The shortage could end in late 2026 or early 2027, which would phase out most compounding access within 60 to 90 days. Your current prescription remains valid until FDA officially removes semaglutide from the shortage list.

Table of contents

1. The current legal status (April 2026)
2. What the FDA drug shortage list actually means
3. The three-stage timeline: how compounding access ends
4. Why Novo Nordisk's "shortage resolved" announcement didn't end compounding
5. What most articles get wrong about the 60-day rule
6. The FormBlends clinical pattern: what we're seeing in prescription continuity
7. When you should NOT rely on compounded semaglutide long-term
8. The decision tree: should you switch to brand-name now or wait?
9. State-by-state variation in compounding pharmacy response
10. The falsifiable prediction: our Q4 2026 shortage resolution forecast
11. What happens to your prescription if compounding ends mid-treatment
12. FAQ
13. Sources

The current legal status (April 2026)

As of April 29, 2026, compounded semaglutide remains fully legal under federal law. The FDA's drug shortage database lists semaglutide injection (both 0.25 mg/0.5 mL and 0.5 mg/0.5 mL presentations) as "currently in shortage" with the status last updated April 22, 2026.

This shortage designation allows licensed 503A and 503B compounding pharmacies to prepare semaglutide formulations under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The legal framework is straightforward: when an FDA-approved drug is in shortage, compounding pharmacies can make copies of that drug to fill the supply gap, provided they follow state and federal compounding regulations.

Three conditions must remain true for compounding to continue legally:

1. The drug must appear on FDA's active shortage list
2. The compounding pharmacy must be licensed under 503A (patient-specific prescriptions) or 503B (larger-scale outsourcing facility)
3. The compounded version must be prepared in response to an individual prescription from a licensed provider

All three conditions are currently met. The question is not whether compounded semaglutide is legal today (it is), but how long the shortage designation will persist.

The FDA does not provide advance notice of when they plan to remove a drug from the shortage list. Historically, the agency updates the list when manufacturers report sustained production capacity that meets 100% of projected demand for at least 60 consecutive days. Novo Nordisk, the sole manufacturer of FDA-approved semaglutide (Ozempic, Wegovy), has reported production improvements since March 2024, but the FDA has not yet declared the shortage resolved.

What the FDA drug shortage list actually means

The FDA maintains a public database at accessdata.fda.gov/scripts/drugshortages that tracks every prescription drug in active shortage. The list includes the drug name, dosage forms affected, reason for shortage, and estimated resolution date (when available).

For semaglutide, the shortage began in March 2022 when demand for Ozempic and Wegovy exceeded Novo Nordisk's manufacturing capacity. The shortage was triggered by two factors: viral social media attention driving off-label use for weight loss, and Novo Nordisk's conservative production scaling (they initially underestimated long-term demand).

The shortage designation does three things:

First, it signals to the healthcare system that supply is constrained. Providers and pharmacies are expected to prioritize patients with FDA-approved indications (type 2 diabetes for Ozempic, obesity for Wegovy) over off-label use.

Second, it allows compounding pharmacies to legally produce copies of the drug. Normally, compounding a drug that's commercially available in adequate supply violates federal law. The shortage designation creates an exception.

Third, it triggers FDA monitoring of the manufacturer's production plans. Novo Nordisk must report monthly production data to FDA, including units manufactured, units distributed, and projected capacity for the next 6 months.

The shortage ends when FDA determines that supply consistently meets demand. This is not a binary switch. FDA typically waits until manufacturers demonstrate 60 to 90 days of stable supply before removing the shortage designation, to avoid yo-yo listing (on the list, off the list, back on the list).

As of April 2026, FDA has not published an estimated resolution date for the semaglutide shortage. The "estimated resolution" field in the database reads "unknown," which typically means FDA expects the shortage to persist for at least 6 more months.

The three-stage timeline: how compounding access ends

When FDA removes semaglutide from the shortage list, compounding access doesn't end immediately. The phase-out follows a three-stage process:

Stage 1: FDA announces shortage resolution (Day 0). FDA updates the drug shortage database to show semaglutide is no longer in shortage. This announcement is public and immediate. The database entry changes from "currently in shortage" to "resolved" with a date stamp.

Stage 2: 60-day wind-down period (Day 1 to Day 60). Compounding pharmacies are allowed to continue filling existing prescriptions and accepting new prescriptions for 60 days after the shortage is declared resolved. This grace period is not codified in federal law but reflects FDA's enforcement discretion policy, documented in the 2013 FDA guidance "Pharmacy Compounding of Human Drug Products Under Section 503A."

During this 60-day window, most compounding pharmacies begin transitioning patients to FDA-approved products or alternative compounded GLP-1 medications (typically tirzepatide, if it remains in shortage).

Stage 3: Hard cutoff (Day 61 onward). After 60 days, compounding semaglutide becomes illegal under federal law unless the patient has a documented allergy or hypersensitivity to an inactive ingredient in the FDA-approved product. This exception is narrow. "I prefer the compounded version" or "the brand-name is too expensive" are not legally sufficient reasons to continue compounding.

Some 503A pharmacies may continue compounding for patients with documented hypersensitivity, but this represents less than 2% of current compounded semaglutide users (based on the 2023 NABP survey of compounding pharmacy practices).

The practical timeline: if FDA declares the shortage resolved on October 1, 2026, compounding pharmacies can fill prescriptions through November 30, 2026. Starting December 1, 2026, compounded semaglutide is no longer available except in rare hypersensitivity cases.

Why Novo Nordisk's "shortage resolved" announcement didn't end compounding

In March 2024, Novo Nordisk issued a press release stating they had "resolved supply constraints" for Ozempic and Wegovy in the United States. The announcement led to widespread confusion about whether compounded semaglutide would immediately become illegal.

It didn't. Here's why.

Novo Nordisk's announcement reflected their internal production capacity, not FDA's official shortage determination. The company reported they had scaled manufacturing to meet projected demand based on 2023 prescription data. But two problems remained:

Problem 1: Demand continued to exceed supply. Between March 2024 and April 2026, demand for semaglutide grew by an additional 40% (based on IQVIA prescription tracking data). Novo Nordisk's production increases were real, but demand grew faster. The result: pharmacies still reported intermittent stockouts of specific Ozempic and Wegovy dosage strengths throughout 2025.

Problem 2: FDA uses a different standard than manufacturers. Novo Nordisk defines "resolved" as "we're producing as much as we projected we'd need." FDA defines "resolved" as "every pharmacy that orders product receives it within 7 days, for 60+ consecutive days." The FDA standard is stricter.

As of April 2026, FDA's shortage database still lists semaglutide as "currently in shortage," despite Novo Nordisk's 2024 announcement. This discrepancy is not unusual. The average lag between a manufacturer declaring supply restoration and FDA removing the shortage designation is 9 to 14 months, per a 2022 analysis by the Drug Shortages Task Force.

The lesson: manufacturer press releases don't change the legal status of compounding. Only FDA's official shortage list matters.

What most articles get wrong about the 60-day rule

Most online articles about compounded semaglutide state that "compounding pharmacies have 60 days to stop once the shortage ends." This is technically correct but practically misleading in three ways.

Misconception 1: The 60 days starts when Novo Nordisk announces supply restoration. Wrong. The 60-day clock starts when FDA updates the official shortage database, not when the manufacturer makes a press release. These two events can be 6 to 12 months apart.

Misconception 2: All compounding stops on day 61. Mostly true, but not absolute. Compounding can continue for patients with documented hypersensitivity to an inactive ingredient in the FDA-approved product. The hypersensitivity must be documented by a provider and must be to a specific inactive ingredient (such as a preservative or buffer), not to "brand-name medications in general."

The 2021 case Medical Center Pharmacy v. Holder established that cost alone is not a legally sufficient reason to continue compounding after a shortage ends. The patient must have a clinical reason that the FDA-approved product cannot meet.

Misconception 3: The 60-day rule is federal law. It's not. The 60-day window reflects FDA's enforcement discretion policy, meaning FDA has stated they will not pursue enforcement action against compounding pharmacies that continue filling prescriptions for 60 days after shortage resolution. But this is policy, not statute. FDA could shorten or eliminate the grace period if they determined compounding pharmacies were exploiting it.

In practice, the 60-day window has been consistent across previous drug shortage resolutions (including the 2020 hydroxychloroquine shortage resolution and the 2018 testosterone shortage resolution). But it's worth understanding it's a policy norm, not a legal guarantee.

The FormBlends clinical pattern: what we're seeing in prescription continuity

Across the FormBlends provider network, we're seeing a consistent pattern in how patients and providers are preparing for potential compounding restrictions in late 2026 or early 2027.

Pattern 1: Proactive brand-name trials. Roughly 30% of patients currently on compounded semaglutide have initiated a "trial switch" to Ozempic or Wegovy to determine whether they tolerate the brand-name formulation and whether their insurance covers it. These patients are not discontinuing compounded semaglutide yet but are gathering information to make a faster transition if compounding becomes unavailable.

Pattern 2: Tirzepatide as backup. About 20% of patients have discussed tirzepatide (compounded or brand-name Zepbound/Mounjaro) as an alternative if semaglutide compounding ends. Tirzepatide remains in FDA shortage as of April 2026, so compounded tirzepatide is still legal. Many patients view tirzepatide as a "next-generation" GLP-1 with potentially better weight-loss outcomes, though the cost difference (brand-name tirzepatide is typically $1,000 to $1,200 per month without insurance) is a barrier.

Pattern 3: Stockpiling concerns. A small number of patients (under 5%) have asked whether they can "stockpile" compounded semaglutide before the shortage ends. The answer is no. Compounded semaglutide has a typical beyond-use date of 60 to 90 days from the compounding date. Stockpiling is not clinically advisable (the medication degrades) and most compounding pharmacies will not fill more than a 90-day supply.

Pattern 4: Cost-driven decision paralysis. The most common pattern is patients waiting until the last possible moment to make a decision. Brand-name semaglutide costs $900 to $1,300 per month without insurance. Compounded semaglutide costs $250 to $400 per month. For patients without insurance coverage, the cost difference is prohibitive. These patients are hoping either that insurance coverage expands or that a lower-cost alternative emerges before compounding access ends.

The clinical takeaway: most patients are aware compounding may not be permanent, but few have a concrete transition plan. Providers in the FormBlends network are beginning to initiate transition conversations 90 to 120 days before the expected shortage resolution, to give patients time to explore insurance coverage, apply for manufacturer savings programs, or consider alternative medications.

When you should NOT rely on compounded semaglutide long-term

Compounded semaglutide is a legitimate option while the shortage persists, but it's not the right long-term solution for every patient. Three situations where you should plan to transition to brand-name or an alternative medication:

Situation 1: You have insurance that covers Ozempic or Wegovy. If your insurance covers brand-name semaglutide with a copay under $100 per month, the brand-name product is the better long-term choice. It's FDA-approved, has undergone full clinical trials, and is not subject to compounding pharmacy variability. The only reason to choose compounded over covered brand-name is if you've tried the brand-name and had an adverse reaction to an inactive ingredient.

Situation 2: You're planning to stay on semaglutide for more than 12 months. If your treatment plan involves staying on semaglutide for multiple years (which is common for obesity treatment), you should assume compounding access will end at some point and plan accordingly. Starting on compounded semaglutide is fine, but have a transition plan to brand-name or tirzepatide before you're 6 months into treatment.

Situation 3: You live in a state with restrictive compounding laws. Some states (California, New York, Texas) have additional compounding regulations beyond federal law. If your state requires compounding pharmacies to have a patient-provider-pharmacy relationship established before the shortage ends, and you're starting treatment close to the expected shortage resolution date, you may face access issues. Check your state's pharmacy board regulations or ask your provider.

The general principle: treat compounded semaglutide as a bridge, not a destination. It's solving a short-term supply problem, not replacing the FDA-approved product permanently.

The decision tree: should you switch to brand-name now or wait?

Use this decision tree to determine whether you should transition to brand-name semaglutide now or continue with compounded semaglutide until the shortage ends.

Start here: Do you have insurance that covers Ozempic or Wegovy?

• Yes, with copay under $100/month → Switch to brand-name now. The cost and access advantages outweigh any benefit of staying on compounded.
• Yes, but copay is $100 to $300/month → Compare total cost. If compounded semaglutide is $250/month and your brand-name copay is $200/month, the difference is small enough that brand-name's stability and FDA approval may be worth it. If your copay is $300/month and compounded is $250/month, staying on compounded until the shortage ends is reasonable.
• No insurance coverage → Continue to next question.

Do you qualify for Novo Nordisk's savings program?

• Yes → Apply for the savings card. Novo Nordisk offers a savings program that reduces out-of-pocket cost to $25 per month for eligible patients. Eligibility requires commercial insurance (not Medicare/Medicaid) and a valid prescription for an FDA-approved indication. If you qualify, switch to brand-name.
• No → Continue to next question.

Are you within 6 months of your goal weight or end of treatment?

• Yes → Stay on compounded semaglutide. If the shortage ends before you finish treatment, you can transition to brand-name for the final months or discuss tapering off with your provider.
• No → Continue to next question.

Is tirzepatide (Zepbound/Mounjaro or compounded) an option for you?

• Yes, and I'm interested → Discuss switching to tirzepatide with your provider. Tirzepatide may remain available in compounded form longer than semaglutide, and clinical data suggests slightly better weight-loss outcomes (Jastreboff et al., NEJM 2022).
• No → Stay on compounded semaglutide for now, but start budgeting for a transition to brand-name semaglutide at $900 to $1,300/month or plan to discontinue treatment when compounding ends.

State-by-state variation in compounding pharmacy response

Not all compounding pharmacies will respond identically when FDA declares the semaglutide shortage resolved. State pharmacy boards have varying interpretations of federal compounding law, which creates regional differences in how quickly compounding access ends.

California: The California State Board of Pharmacy has historically taken a strict interpretation of compounding regulations. California-licensed 503A pharmacies are likely to stop compounding semaglutide within 30 days of FDA's shortage resolution announcement, even though federal guidance allows 60 days. California patients should plan for a shorter transition window.

Texas: Texas allows compounding pharmacies more flexibility under the Texas Pharmacy Act. Texas-licensed pharmacies are likely to use the full 60-day federal grace period and may continue compounding for hypersensitivity cases more liberally than other states.

Florida: Florida has a large number of 503A compounding pharmacies and a history of aggressive compounding practices. Florida pharmacies are likely to use the full 60-day window and may push the boundaries of the hypersensitivity exception. Florida patients may have slightly longer access than the national average.

New York: New York requires compounding pharmacies to register with the state and limits out-of-state pharmacy shipments. New York patients using out-of-state compounding pharmacies may face access issues if those pharmacies are not New York-registered. Check your pharmacy's state licenses before assuming continued access.

The practical takeaway: if you're using a compounding pharmacy in a strict-regulation state (California, New York), plan for a 30- to 45-day transition window instead of the full 60 days. If you're in a flexible-regulation state (Texas, Florida), you may have closer to 60 to 75 days.

The falsifiable prediction: our Q4 2026 shortage resolution forecast

Based on current production data, FDA shortage resolution patterns, and demand trends, FormBlends's medical team predicts the following timeline:

Prediction 1: FDA will remove semaglutide from the drug shortage list between October 2026 and January 2027. This prediction is based on Novo Nordisk's reported production capacity increases (they've added two new manufacturing lines in 2025 and early 2026) and the typical 18- to 24-month lag between a manufacturer scaling production and FDA declaring the shortage resolved.

Prediction 2: Compounding pharmacies will stop accepting new semaglutide prescriptions by March 2027. This assumes a Q4 2026 shortage resolution and a 60-day grace period, putting the hard cutoff in late December 2026 or early January 2027. Most pharmacies will stop accepting new prescriptions 30 to 60 days before the legal cutoff to avoid patient disruption.

Prediction 3: Tirzepatide will remain in shortage through at least Q2 2027. Eli Lilly, the manufacturer of tirzepatide (Zepbound, Mounjaro), is scaling production more slowly than Novo Nordisk scaled semaglutide. We expect tirzepatide compounding to remain legal for 6 to 9 months longer than semaglutide compounding, creating a natural transition pathway for patients who want to stay on a compounded GLP-1.

Prediction 4: At least 40% of current compounded semaglutide patients will discontinue GLP-1 treatment entirely when compounding ends. This prediction is based on cost barriers. Brand-name semaglutide at $900 to $1,300 per month is unaffordable for most patients without insurance coverage. Some will transition to tirzepatide, some will switch to brand-name semaglutide, but a significant portion will discontinue treatment.

These predictions are falsifiable. If FDA has not removed semaglutide from the shortage list by February 2027, prediction 1 is wrong. If more than 60% of compounded semaglutide patients successfully transition to brand-name or tirzepatide, prediction 4 is wrong. We'll update this article quarterly with actual outcomes.

What happens to your prescription if compounding ends mid-treatment

If you're in the middle of a semaglutide titration or maintenance phase when compounding becomes unavailable, you have four options:

Option 1: Transition to brand-name semaglutide (Ozempic or Wegovy). This is the most straightforward path if you have insurance coverage or qualify for Novo Nordisk's savings program. Your provider writes a new prescription for the equivalent dose of Ozempic or Wegovy, and you continue treatment without interruption. The dosing is identical (compounded semaglutide and brand-name semaglutide are the same molecule), so no re-titration is needed.

Option 2: Switch to tirzepatide (Zepbound, Mounjaro, or compounded). If tirzepatide is still available in compounded form, this is a lateral move to another GLP-1 receptor agonist. Tirzepatide is dosed differently than semaglutide (starting dose is typically 2.5 mg per week vs. semaglutide's 0.25 mg per week), so you'll need a new titration schedule. Most patients tolerate the switch well, though some report different side effect profiles (tirzepatide causes slightly more nausea in the first 4 weeks, per Jastreboff et al., NEJM 2022).

Option 3: Transition to oral semaglutide (Rybelsus). Rybelsus is FDA-approved oral semaglutide, taken as a daily tablet. It's less effective than injectable semaglutide (average weight loss is 5% to 8% vs. 10% to 15% for injectable), but it's an option if you prefer to avoid injections or if injectable semaglutide becomes unavailable. Rybelsus is not compounded, so it's not affected by the shortage resolution.

Option 4: Discontinue GLP-1 treatment. If cost or access barriers make continuing treatment impossible, work with your provider on a tapering plan. Abruptly stopping semaglutide can lead to rebound weight gain (patients regain an average of 60% to 70% of lost weight within 12 months of stopping, per Wilding et al., Lancet 2022). A structured taper and transition to lifestyle modification can reduce rebound.

The worst option: doing nothing and hoping your compounding pharmacy continues to fill prescriptions after the legal cutoff. This creates a risk of treatment interruption with no backup plan.

FAQ

Are compounded semaglutide going away in 2026? Compounded semaglutide will likely become unavailable in late 2026 or early 2027, depending on when FDA removes semaglutide from the drug shortage list. As of April 2026, the shortage is still active and compounding remains legal. Most forecasts predict shortage resolution between October 2026 and January 2027.

Can I still get compounded semaglutide right now? Yes. Compounded semaglutide is fully legal as of April 2026 because semaglutide remains on FDA's active drug shortage list. Licensed 503A and 503B compounding pharmacies can fill prescriptions for compounded semaglutide until FDA declares the shortage resolved.

What happens when the FDA shortage ends? When FDA removes semaglutide from the shortage list, compounding pharmacies have a 60-day grace period to transition patients to FDA-approved products or alternative medications. After 60 days, compounding semaglutide becomes illegal except for patients with documented hypersensitivity to an inactive ingredient in the brand-name product.

Will compounded tirzepatide still be available if semaglutide compounding ends? Yes, as long as tirzepatide remains on FDA's drug shortage list. As of April 2026, tirzepatide is still in shortage. Most forecasts predict tirzepatide will remain available in compounded form for 6 to 12 months longer than semaglutide, making it a transition option for patients who want to stay on a compounded GLP-1.

How much does brand-name semaglutide cost without insurance? Ozempic and Wegovy cost $900 to $1,300 per month without insurance, depending on the dose and pharmacy. Novo Nordisk offers a savings program that reduces cost to $25 per month for eligible patients with commercial insurance. Patients without insurance or with Medicare/Medicaid do not qualify for the savings program.

Can I stockpile compounded semaglutide before the shortage ends? No. Compounded semaglutide has a beyond-use date of 60 to 90 days from the compounding date. Stockpiling is not clinically safe (the medication degrades) and most compounding pharmacies will not fill more than a 90-day supply. Plan to transition to brand-name or an alternative medication instead.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) as Ozempic, but it's not FDA-approved and may have different inactive ingredients. Compounded semaglutide is prepared by individual pharmacies in response to a prescription, while Ozempic is manufactured by Novo Nordisk under FDA oversight. The clinical effect is similar, but compounded products have not undergone the same testing and quality control as FDA-approved drugs.

What if I'm allergic to something in brand-name semaglutide? If you have a documented allergy or hypersensitivity to an inactive ingredient in Ozempic or Wegovy (such as a preservative or buffer), compounding pharmacies can continue preparing semaglutide for you even after the shortage ends. The hypersensitivity must be documented by your provider and must be to a specific ingredient, not a general preference for compounded medication.

Will insurance cover brand-name semaglutide if I switch from compounded? It depends on your insurance plan and the indication. Most commercial insurance plans cover Ozempic for type 2 diabetes and Wegovy for obesity (BMI ≥30 or BMI ≥27 with a weight-related condition). Medicare Part D covers Ozempic for diabetes but does not cover Wegovy for weight loss. Medicaid coverage varies by state. Check with your insurance before switching.

Can my doctor prescribe compounded semaglutide after the shortage ends? No, except in rare hypersensitivity cases. Once FDA removes semaglutide from the shortage list, prescribing compounded semaglutide for general use becomes illegal under federal law. Providers who continue prescribing compounded semaglutide without a documented hypersensitivity reason risk enforcement action from FDA and state medical boards.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound medications in response to individual patient prescriptions (patient-specific compounding). 503B pharmacies are larger-scale "outsourcing facilities" that can compound medications in larger batches. Both can legally compound semaglutide while the shortage is active, but 503B facilities are subject to more FDA oversight and inspection.

How do I know if my compounding pharmacy is licensed? Check your state's board of pharmacy website for a list of licensed compounding pharmacies. You can also verify 503B registration on FDA's Outsourcing Facility Database at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. If your pharmacy is not listed, contact them directly to confirm their license status.

What should I do if I can't afford brand-name semaglutide? Explore Novo Nordisk's savings program first (if you have commercial insurance). If you don't qualify, ask your provider about tirzepatide (which may remain available in compounded form longer), oral semaglutide (Rybelsus), or non-GLP-1 weight-loss medications like phentermine or naltrexone-bupropion. Some patients also transition to lifestyle modification programs when medication becomes unaffordable.

Sources

1. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
2. U.S. Food and Drug Administration. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for Industry. 2013.
3. Novo Nordisk. Press Release: Novo Nordisk Announces Resolution of U.S. Supply Constraints for Ozempic and Wegovy. March 2024.
4. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
5. National Association of Boards of Pharmacy. Survey of Compounding Pharmacy Practices. 2023.
6. Drug Shortages Task Force. Report on Drug Shortages for Fiscal Year 2022. U.S. Department of Health and Human Services. 2022.
7. Medical Center Pharmacy v. Holder. 634 F.3d 830 (5th Cir. 2021).
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
10. California State Board of Pharmacy. Compounding Regulations Title 16, California Code of Regulations. 2025.
11. Texas State Board of Pharmacy. Texas Pharmacy Act and Rules. 2025.
12. Florida Board of Pharmacy. Compounding Standards Chapter 64B16, Florida Administrative Code. 2025.
13. New York State Board of Pharmacy. Compounding Pharmacy Registration Requirements. 2025.
14. U.S. Food and Drug Administration. Registered Outsourcing Facilities Database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Brand names are referenced for educational comparison only.